Drug intelligence / Profile preview

Discovery campaign #2

Development stage: Preclinical
Lead developer: Oncko
Modality: Small Molecules

Overview

Discovery campaign #2 is a preclinical-stage therapeutic program being developed by Oncko. It consists of a multi-drug combination regimen specifically designed to target resistance mechanisms in second-line non-small cell lung cancer (2L NSCLC). While the specific molecular targets and individual components of the regimen remain undisclosed, the program focuses on overcoming treatment resistance, a major hurdle in the management of advanced lung cancer. The development is currently in the discovery phase, aiming to identify optimal resistance-targeting regimens.

Beyond the preview

Go deeper on Discovery campaign #2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Discovery campaign #2.

Explore the full profile